Y-K Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki SR Park, H-Y Lim, J Wu, B Langer, MA Shah on behalf of AVAGAST investigators AVAGAST: a randomized, double-blind.

Slides:



Advertisements
Similar presentations
FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
Advertisements

Metastatic Gastric Cancer
Facon T et al. Proc ASH 2013;Abstract 2.
1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
AVADO PFS Analysis (ITT Population) All P values vs. placebo Adapted from Miles et al. ASCO 2008, abstract LBA 1011.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Placebo + Trastuzumab + Docetaxel vs.
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.
A Randomized, Double-blind, Placebo-controlled, Phase IIIb Trial (ATLAS) Comparing Bevacizumab Therapy with or without Erlotinib, after Completion of Chemotherapy.
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.
RIBBON-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy with or without Bevacizumab for First-Line Treatment of HER2-Negative.
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.
Poster #382 XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated.
Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.
Axel Grothey, MD Professor of Oncology Mayo Clinic Rochester, Minnesota Strategies to Improve Patient Outcomes in Gastric and Gastroesophageal Junction.
Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.
Quality of life results from a Phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer Taroh.
E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
Overview of Targeted Therapies for Esophageal and Gastric Cancers Johanna Bendell, MD Director, GI Oncology Research Associate Director, Drug Development.
KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.
XELOX vs. FOLFOX4: survival and response results from XELOX-1 / NO16966, a randomized phase III trial of first-line treatment for patients with metastatic.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
The Combination of Bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) is highly active in advanced colorectal.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
Niall C. Tebbutt International randomised phase III study of capecitabine, bevacizumab, and mitomycin C in first-line treatment of metastatic colorectal.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
CB-1 Background of Pancreatic Cancer & NCIC CTG PA.3 Study Design Malcolm Moore, MD Professor of Medicine and Pharmacology Princess Margaret Hospital Chair,
Tolerability of fluoropyrimidines differs by region Daniel G. Haller on behalf of: Cassidy J, Clarke S, Cunningham D, Van Cutsem E Hoff P, Rothenberg M,
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.
Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
Phase III Study of First-Line XELOX Plus Bevacizumab (BEV) for 6 Cycles Followed by XELOX Plus BEV or Single Agent (s/a) BEV as Maintenance Therapy in.
A three-arm randomized phase III trial of FOLFOX4 vs FOLFOX4 + bevacizumab vs XELOX + bevacizumab in the adjuvant treatment of patients with stage III.
A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
Mok TS, Wu SL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: Gefitinib Superior.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Pazopanib in Advanced Ovarian Cancer: A new galloping horse. Dr. Raafat Ragaie, MD,FRCR.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
Alessandra Gennari, MD PhD
Gajria D et al. Proc SABCS 2010;Abstract P
Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors of Survival J Tabernero,
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
The Evolving Standard of Care in Gastric Cancer
Final results of the phase III, randomised, double-blind AVOREN trial of first-line bevacizumab + interferon-a2a in metastatic renal cell carcinoma Escudier.
Bevacizumab in platinum-sensitive ovarian cancer: OCEANS.
Baselga J et al. SABCS 2009;Abstract 45.
First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.
1University Hospital Gasthuisberg, Leuven, Belgium;
for the Cancer and Leukemia Group B
and the NSABP Investigators
Presentation transcript:

Y-K Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki SR Park, H-Y Lim, J Wu, B Langer, MA Shah on behalf of AVAGAST investigators AVAGAST: a randomized, double-blind placebo-controlled, phase III study of first-line capecitabine and cisplatin + bevacizumab or placebo in patients with advanced gastric cancer (AGC)

Rationale for Bevacizumab in AGC Angiogenesis important for tumor growth, progression and metastases Vascular endothelial growth factor (VEGF): – Critical growth factor for tumor angiogenesis – Over-expressed and prognostic for many human tumors Bevacizumab: – Humanized monoclonal antibody to VEGF – Effective and safe in mCRC and other tumor types – Promising results in Phase II studies in AGC 1 1 Shah et al. J Clin Oncol 2006;23:2574–2576

AVAGAST: A Randomized Double-Blind Placebo- Controlled Phase III Study Starting dose of bev/placebo: 30 minutes, subsequent doses: 15 minutes Capecitabine*/Cisplatin (XP) + Placebo q3w Capecitabine*/Cisplatin (XP) + Bevacizumab q3w Locally advanced or metastatic gastric cancer R *5-FU also allowed if cape contraindicated Cape 1000 mg/m 2 oral bid, d1–14, 1-week rest Cisplatin 80 mg/m 2 d1 Bevacizumab 7.5 mg/kg d1 Maximum of 6 cycles of cisplatin Cape and bevacizumab/placebo until PD Stratification factors: 1. Geographic region 2. Fluoropirimidine backbone 3. Disease status

Endpoints and Statistical Assumptions Primary: overall survival Secondary: PFS, TTP, ORR, duration of response, safety, QoL, biomarkers Statistical assumptions  Median overall survival improvement from 10.0 to 12.8 months (HR 0.78)  Two-sided α-level = 0.05, 80% power  Required sample size: 760 patients for 517 deaths (with interim analysis)

Main Eligibility Criteria Metastatic or inoperable, locally advanced adenocarcinoma of the stomach or gastro-esophageal junction (GEJ) Measurable or evaluable disease ECOG performance status 0–2 No previous chemotherapy for metastatic/locally advanced gastric cancer If adjuvant chemotherapy, completed at least 6 months prior to randomization No previous platinum or antiangiogenic therapy No history of other malignancies

Trial Conduct From September 2007 to December 2008, 774 patients were enrolled A total of 93 centers in 17 countries were involved Interim analysis –Planned at 345 events, but not performed according to protocol as analysis date too close to anticipated final analysis Data cutoff for final analysis –November 2009 –After 509 events

Patient Characteristics (I) Number of patients N=774 (%) XP + Placebo N=387 XP + Bev N=387 GenderMale258 (67)257 (66) Age, yearsMedian (range)59 (22–82)58 (22–81) ECOG PS0–1 ≥2 367 (95) 20 (5) 365 (94) 22 * (6) RegionAsia Europe Pan-America 188 (49) 124 (32) 75 (19) 188 (49) 125 (32) 74 (19) FluoropyrimidineCapecitabine 5-FU 365 (94) 22 (6) 364 (94) 23 (6) Disease statusLocally advanced Metastatic 9 (2) 378 (98) 20 (5) 367 (95) *1 additional patient had an ECOG PS of 4

Patient Characteristics (II) Number of patients N=774 (%) XP + Placebo N=387 XP + Bev N=387 Primary site Stomach GEJ 338 (87) 49 (13) 333 (86) 54 (14) Histologic type Intestinal Diffuse Mixed 135 (35) 206 (53) 26 (7) 155 (40) 176 (46) 35 (9) Disease measurability Measurable Evaluable 297 (77) 90 (23) 311 (80) 76 (20) Metastatic sites, n 0 1 ≥2 8 (2) 131 (34) 247 (64) 8 (2) 131 (34) 247 (64) Prior gastrectomyYes107 (28)110 (28) Liver metastasisYes126 (33)130 (34)

Overall Survival XP + Placebo XP + Bev Number at risk XP + Placebo XP + Bev HR = % CI 0.73–1.03 p = Survival rate Study month

Progression-Free Survival XP + Placebo XP + Bev Number at risk XP + Placebo XP + Bev HR = % CI 0.68–0.93 p = Progression-free survival rate Study month

Best Overall Response: Measurable Disease Population XP + Placebo N=387 XP + Bev N=387 Patients with measurable disease Overall response111 (37%)143 (46%) 95% CI31.9– –51.7 Difference9% 95% CI0.6–16.6 P value (  2 ) Complete response3 (1%)5 (2%) Partial response108 (36%)138 (44%) Stable disease90 (30%)93 (30%) Progressive disease63 (21%)44 (14%) Not assessable33 (11%)31 (10%)

Overall Survival: Subgroup Analysis Pan-America * 29 patients with locally advanced disease only

Regional Differences in Efficacy Region XP + Placebo Median, mo XP + Bev Median, mo Delta, mo Hazard Ratio95% CI OSAsia –1.25 Europe –1.14 America –0.94 PFSAsia –1.14 Europe –0.93 America –0.93

Patient Characteristics by Region % of patientsAsiaEuropePan-America Age< ≥ ECOG PS0– *94 Primary siteStomach GEJ62216 Extent of diseaseMetastatic Locally advanced158 Prior gastrectomyyes no Measurable lesionyes no Liver metastasisyes no *1 additional patient had an ECOG PS of 4

Second-Line Therapy by Region Region Patients entered Patients receiving second-line treatment% Asia Europe Pan-America

Most Frequent Grade 3–5 AEs (≥5%) % of patients XP + Placebo N=381 XP + Bev N=386 Neutropenia3735 Febrile neutropenia45 Anemia1410 Decreased appetite118 Nausea107 Vomiting96 Diarrhea48 Hypokalemia63 Asthenia65 Hand-foot syndrome36 Hypertension<16 Pulmonary embolism53 Fatigue45

AEs of Special Interest to Bevacizumab % of patients XP + Placebo (N=381)XP + Bev (N=386) TotalG1G2G3G4G5TotalG1G2G3G4G5 Patients with ≥1 AE (all body systems) VTEs12< <1343– ATEs2<1–11–2 – Bleeding151123< <1 Hypertension1367<1––21796–– Proteinuria623–––734<1–– Wound complications <1 –––2 –– GI perforations<1– –– 2––2– CHF<1–– –– – – Fistula/abscess in 2 patients on XP + Bev Reversible posterior leukoencephalopathy syndrome in 2 patients on XP + Bev

AVAGAST Summary & Conclusions Primary endpoint of OS not met Secondary efficacy endpoints (PFS, best ORR) significantly improved, indicating clinical activity of bev + chemo in AGC Heterogeneous efficacy results in both treatment arms across geographic regions  Hypothesis generating with regard to tumor burden, patient status, practice patterns, genetics? No unexpected / new safety signals for bev Further analysis ongoing, including preplanned biomarker analysis

Acknowledgments Patients and their families Investigators, study coordinators and nurses at 93 centers in 17 countries AVAGAST study team at Genentech, Roche & Chugai